Study of microRNAs as a Diagnostic Tool for HCV-related Hepatocellular Carcinoma
NCT ID: NCT03429530
Last Updated: 2018-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2018-02-15
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
NCT05449847
Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma
NCT02507882
MicroRNAs as Diagnostic Biomarkers in Hepatocellular Carcinoma Among Somali Patients
NCT03227510
FAST (Focused Abbreviated Screening Technique)-MRI Study
NCT04539717
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
NCT00629421
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
miRNAs expression profile analysis has allowed the characterization of 'identity' associated with each type of human cancer and this 'identity' is correlated with carcinogenesis, tumor progression, and response to tumor treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1
20 patients with chronic HCV
No interventions assigned to this group
GroupII
20 patient with chronic HCV related liver cirrhosis
No interventions assigned to this group
GroupIII
40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
No interventions assigned to this group
group IV
20 healthy blood donors will also be included as a control group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of HCV will be based on detection of anti-HCV antibodies
* Diagnosis of liver cirrhosis will be based on ultrasonography, biochemically and elastography when available
* Diagnosis of HCC will be based on ultrasonography, the typical criteria in triphasic multislice CT scan
Exclusion Criteria
* serological evidence of human immunodeficiency virus (HIV) infection
* malignancy in other organs
* After intervention in treatment of hepatocellular carcinoma
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HMHamed
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HMHamed
DR Hager
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
miRNA in HCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.